{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T23:55:22Z","timestamp":1788479722211,"version":"build-2803163510"},"reference-count":58,"publisher":"The Endocrine Society","issue":"12","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Prolactinomas are the most frequent subtype of hormone-secreting pituitary adenomas, comprising about 50%, of which more than 70% are microprolactinomas. Treatment with oral dopamine agonists (DAs) has been the mainstay of treatment for macroprolactinoma for many decades, with cabergoline being the drug of choice in most instances. DAs are highly effective; prolactin normalization and tumor shrinkage are observed in close to 90% of patients. Twenty-five percent of patients can be withdrawn from cabergoline after 2 years of treatment. However, medication side effects, the need for longer-term therapy in most patients, dopamine resistance, or poor compliance affect overall utility. Endoscopic transsphenoidal surgery (TSS) using modern methods has a similarly high success rate in treating microprolactinomas, with surgical remission rates of 80% to 95% or more reported in many series. Long-term remission rates of 75% are generally observed. In the hands of experienced pituitary surgeons, TSS is very safe, with morbidities at less than 1% and mortality rates of 0%. Cost-wise, cabergoline therapy is less expensive, although the long-term differences in cost are not substantial. The goal of this editorial is to debate the pros and cons of surgery as a first-line option for the treatment of macroprolactinoma, presenting the views of an expert endocrinologist and pituitary surgeon both against and in favor of surgery.<\/jats:p>","DOI":"10.1210\/clinem\/dgaf434","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T12:01:38Z","timestamp":1759233698000},"page":"e4242-e4247","source":"Crossref","is-referenced-by-count":3,"title":["Debate: Surgery as Initial Therapy for Microprolactinoma"],"prefix":"10.1210","volume":"110","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8492-3587","authenticated-orcid":false,"given":"Mark E","family":"Molitch","sequence":"first","affiliation":[{"name":"Division of Endocrinology, Metabolism and Molecular Medicine, Northwestern University Feinberg School of Medicine , Chicago, IL 60611 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4245-6431","authenticated-orcid":false,"given":"Adam N","family":"Mamelak","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Cedars-Sinai Medical Center , Los Angeles, CA 90048 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2025,10,1]]},"reference":[{"issue":"5","key":"2025111718525694000_dgaf434-B1","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1001\/jama.2016.19699","article-title":"Diagnosis and treatment of pituitary adenomas: a review","volume":"317","author":"Molitch","year":"2017","journal-title":"JAMA"},{"issue":"3","key":"2025111718525694000_dgaf434-B2","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/j.1365-2265.2009.03667.x","article-title":"Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK)","volume":"72","author":"Fernandez","year":"2010","journal-title":"Clin Endocrinol"},{"issue":"9","key":"2025111718525694000_dgaf434-B3","doi-asserted-by":"crossref","first-page":"4268","DOI":"10.1210\/jc.2010-0537","article-title":"Incidence of pituitary adenomas in Northern Finland in 1992-2007","volume":"95","author":"Raappana","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2025111718525694000_dgaf434-B4","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1530\/EJE-14-0144","article-title":"The incidence rate of pituitary adenomas in western Sweden for the period 2001-2011","volume":"171","author":"Tjornstrand","year":"2014","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2025111718525694000_dgaf434-B5","doi-asserted-by":"crossref","first-page":"101290","DOI":"10.1016\/j.beem.2019.101290","article-title":"The epidemiology, diagnosis and treatment of prolactinomas: the old and the new","volume":"33","author":"Chanson","year":"2019","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"5","key":"2025111718525694000_dgaf434-B6","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1210\/er.2005-9998","article-title":"Advances in the treatment of prolactinomas","volume":"27","author":"Gillam","year":"2006","journal-title":"Endocr Rev"},{"issue":"12","key":"2025111718525694000_dgaf434-B7","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/s41574-023-00886-5","article-title":"Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement","volume":"19","author":"Petersenn","year":"2023","journal-title":"Nat Rev Endocrinol"},{"issue":"2","key":"2025111718525694000_dgaf434-B8","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1210\/jc.2010-1692","article-title":"Diagnosis and treatment of hyperprolactinemia: an endocrine society clinical practice guideline","volume":"96","author":"Melmed","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"14","key":"2025111718525694000_dgaf434-B9","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1056\/NEJM199410063311403","article-title":"A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group","volume":"331","author":"Webster","year":"1994","journal-title":"N Engl J Med"},{"issue":"16","key":"2025111718525694000_dgaf434-B10","first-page":"753","article-title":"Hyperprolactinemic amenorrhea:treatment with cabergoline versus bromocriptine. Results of a national multicenter randomized double-blind study","volume":"24","author":"Pascal-Vigneron","year":"1995","journal-title":"Presse Med"},{"issue":"11","key":"2025111718525694000_dgaf434-B11","doi-asserted-by":"crossref","first-page":"5256","DOI":"10.1210\/jcem.86.11.8054","article-title":"Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy","volume":"86","author":"Di Sarno","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2025111718525694000_dgaf434-B12","doi-asserted-by":"crossref","first-page":"e4558","DOI":"10.1210\/clinem\/dgaa652","article-title":"Predictors of the response to dopaminergic therapy in patients with prolactinoma","volume":"105","author":"Hage","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2025111718525694000_dgaf434-B13","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1210\/clinem\/dgad174","article-title":"Approach to the patient with prolactinoma","volume":"108","author":"Auriemma","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2025111718525694000_dgaf434-B14","doi-asserted-by":"crossref","first-page":"R89","DOI":"10.1530\/EJE-16-0087","article-title":"THERAPY OF ENDOCRINE DISEASE: surgery in microprolactinomas: effectiveness and risks based on contemporary literature","volume":"175","author":"Tampourlou","year":"2016","journal-title":"Eur J Endocrinol"},{"issue":"12","key":"2025111718525694000_dgaf434-B15","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1007\/s40618-021-01569-6","article-title":"First-line surgery in prolactinomas: lessons from a long-term follow-up study in a tertiary referral center","volume":"44","author":"Andereggen","year":"2021","journal-title":"J Endocrinol Invest"},{"issue":"1","key":"2025111718525694000_dgaf434-B16","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/s10143-023-02033-0","article-title":"Surgery as first-line treatment for prolactinoma? Discussion of the literature and results of a consecutive series of surgically treated patients","volume":"46","author":"Ottenhausen","year":"2023","journal-title":"Neurosurg Rev"},{"key":"2025111718525694000_dgaf434-B17","doi-asserted-by":"crossref","first-page":"e1180","DOI":"10.1016\/j.wneu.2020.02.145","article-title":"Geographic variation in costs of transsphenoidal pituitary surgery in the United States","volume":"149","author":"Asemota","year":"2021","journal-title":"World Neurosurg"},{"issue":"3","key":"2025111718525694000_dgaf434-B18","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1210\/clinem\/dgz144","article-title":"Surgery as a viable alternative first-line treatment for prolactinoma patients. A systematic review and meta-analysis","volume":"105","author":"Najafabadi","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2025111718525694000_dgaf434-B19","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1007\/s11102-021-01168-x","article-title":"Surgery is a safe, effective first-line treatment modality for noninvasive prolactinomas","volume":"24","author":"Park","year":"2021","journal-title":"Pituitary"},{"issue":"4","key":"2025111718525694000_dgaf434-B20","first-page":"244","article-title":"The endonasal microscopic approach for pituitary adenomas and other parasellar tumors: a 10-year experience","volume":"63","author":"Fatemi","year":"2008","journal-title":"Neurosurgery"},{"issue":"4","key":"2025111718525694000_dgaf434-B21","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1227\/01.NEU.0000325725.77132.90","article-title":"Pituitary hormonal loss and recovery after transsphenoidal adenoma removal","volume":"63","author":"Fatemi","year":"2008","journal-title":"Neurosurgery"},{"issue":"6","key":"2025111718525694000_dgaf434-B22","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1080\/17446651.2022.2131531","article-title":"Surgery as a first-line option for prolactinomas","volume":"17","author":"Mamelak","year":"2022","journal-title":"Expert Rev Endocrinol Metab"},{"issue":"3","key":"2025111718525694000_dgaf434-B23","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s11102-012-0437-1","article-title":"Single-surgeon fully endoscopic endonasal transsphenoidal surgery: outcomes in three-hundred consecutive cases","volume":"16","author":"Mamelak","year":"2013","journal-title":"Pituitary"},{"issue":"10","key":"2025111718525694000_dgaf434-B24","doi-asserted-by":"crossref","first-page":"4709","DOI":"10.1210\/jc.2003-030461","article-title":"Transsphenoidal surgery for pituitary tumors in the United States, 1996-2000: mortality, morbidity, and the effects of hospital and surgeon volume","volume":"88","author":"Barker","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2025111718525694000_dgaf434-B25","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/s11102-010-0280-1","article-title":"Endoscopic endonasal approach for pituitary adenoma: surgical complications in 301 patients","volume":"14","author":"Gondim","year":"2011","journal-title":"Pituitary"},{"issue":"9","key":"2025111718525694000_dgaf434-B26","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1016\/j.clineuro.2013.02.016","article-title":"Transsphenoidal microsurgical results of female patients with prolactinomas","volume":"115","author":"Ikeda","year":"2013","journal-title":"Clin Neurol Neurosurg"},{"issue":"4","key":"2025111718525694000_dgaf434-B27","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1227\/01.NEU.0000255354.64077.66","article-title":"Graded repair of cranial base defects and cerebrospinal fluid leaks in transsphenoidal surgery","volume":"60","author":"Esposito","year":"2007","journal-title":"Oper Neurosurg"},{"issue":"2","key":"2025111718525694000_dgaf434-B28","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/00006123-199902000-00006","article-title":"Transsphenoidal microsurgical therapy of prolactinomas: initial outcomes and long-term results","volume":"44","author":"Tyrrell","year":"1999","journal-title":"Neurosurgery"},{"issue":"3","key":"2025111718525694000_dgaf434-B29","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s11102-010-0283-y","article-title":"Pituitary surgery for small prolactinomas as an alternative to treatment with dopamine agonists","volume":"14","author":"Babey","year":"2011","journal-title":"Pituitary"},{"issue":"3","key":"2025111718525694000_dgaf434-B30","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s11102-020-01039-x","article-title":"Do nothing but observe microprolactinomas: when and how to replace sex hormones?","volume":"23","author":"Bonert","year":"2020","journal-title":"Pituitary"},{"issue":"2","key":"2025111718525694000_dgaf434-B31","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1365-2265.2006.02562.x","article-title":"Guidelines of the pituitary society for the diagnosis and management of prolactinomas","volume":"65","author":"Casanueva","year":"2006","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"2025111718525694000_dgaf434-B32","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/nrendo.2011.37","article-title":"Medical treatment of prolactinomas","volume":"7","author":"Colao","year":"2011","journal-title":"Nat Rev Endocrinol"},{"issue":"3","key":"2025111718525694000_dgaf434-B33","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1210\/js.2017-00038","article-title":"Cabergoline tapering is almost always successful in patients with macroprolactinomas","volume":"1","author":"Paepegaey","year":"2017","journal-title":"J Endocr Soc"},{"issue":"6","key":"2025111718525694000_dgaf434-B34","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1517\/13543784.11.6.787","article-title":"Dopamine receptor agonists for treating prolactinomas","volume":"11","author":"Colao","year":"2002","journal-title":"Expert Opin Investig Drugs"},{"issue":"12","key":"2025111718525694000_dgaf434-B35","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1001\/jamainternmed.2014.5262","article-title":"Reports of pathological gambling, hypersexuality, and compulsive shopping associated with dopamine receptor agonist drugs","volume":"174","author":"Moore","year":"2014","journal-title":"JAMA Intern Med"},{"issue":"2","key":"2025111718525694000_dgaf434-B36","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s12020-015-0727-2","article-title":"Treating prolactinomas with dopamine agonists: always worth the gamble?","volume":"51","author":"Noronha","year":"2016","journal-title":"Endocrine"},{"issue":"6","key":"2025111718525694000_dgaf434-B37","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1111\/cen.12375","article-title":"Impulse control disorders in patients with dopamine agonist-treated prolactinomas and nonfunctioning pituitary adenomas: a case-control study","volume":"80","author":"Bancos","year":"2014","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2025111718525694000_dgaf434-B38","doi-asserted-by":"crossref","first-page":"492","DOI":"10.3389\/fphar.2017.00492","article-title":"Pulmonary artery occlusion and mediastinal fibrosis in a patient on dopamine agonist treatment for hyperprolactinemia","volume":"8","author":"Su","year":"2017","journal-title":"Front Pharmacol"},{"issue":"12","key":"2025111718525694000_dgaf434-B39","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1007\/BF03345662","article-title":"Cabergoline therapy and the risk of cardiac valve regurgitation in patients with hyperprolactinemia: a meta-analysis from clinical studies","volume":"31","author":"Bogazzi","year":"2008","journal-title":"J Endocrinol Invest"},{"issue":"1","key":"2025111718525694000_dgaf434-B40","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1056\/NEJMp068265","article-title":"Drugs and valvular heart disease","volume":"356","author":"Roth","year":"2007","journal-title":"N Engl J Med"},{"issue":"2","key":"2025111718525694000_dgaf434-B41","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1210\/jc.2018-01071","article-title":"A meta-analysis of the prevalence of cardiac valvulopathy in hyperprolactinemic patients treated with Cabergoline","volume":"104","author":"Stiles","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2025111718525694000_dgaf434-B42","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1111\/j.1742-1241.2008.01779.x","article-title":"Treatment with low doses of cabergoline is not associated with increased prevalence of cardiac valve regurgitation in patients with hyperprolactinaemia","volume":"62","author":"Bogazzi","year":"2008","journal-title":"Int J Clin Pract"},{"issue":"1","key":"2025111718525694000_dgaf434-B43","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11102-019-01016-z","article-title":"Surgery for prolactinomas: a better choice?","volume":"23","author":"Honegger","year":"2020","journal-title":"Pituitary"},{"issue":"6","key":"2025111718525694000_dgaf434-B44","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1210\/clinem\/dgad758","article-title":"Presurgical medical treatment in prolactinomas: surgical implications and pathological characteristics from 290 cases","volume":"109","author":"Chen","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2025111718525694000_dgaf434-B45","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s11102-010-0261-4","article-title":"Effect of dopaminergic drug treatment on surgical findings in prolactinomas","volume":"14","author":"Menucci","year":"2011","journal-title":"Pituitary"},{"key":"2025111718525694000_dgaf434-B46","doi-asserted-by":"crossref","first-page":"bcr2017220971","DOI":"10.1136\/bcr-2017-220971","article-title":"Cabergoline-induced fibrosis of prolactinomas: a neurosurgical perspective","volume":"2017","author":"Mohan","year":"2017","journal-title":"BMJ Case Rep"},{"issue":"02","key":"2025111718525694000_dgaf434-B47","doi-asserted-by":"crossref","first-page":"e66","DOI":"10.1055\/s-0044-1786740","article-title":"The effect of preoperative cabergoline on prolactinoma fibrosis: a case series","volume":"85","author":"Pecorari","year":"2024","journal-title":"J Neurol Surg Rep"},{"key":"2025111718525694000_dgaf434-B48","author":"Mamelak"},{"issue":"1","key":"2025111718525694000_dgaf434-B49","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1210\/jc.2009-1238","article-title":"Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis","volume":"95","author":"Dekkers","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2025111718525694000_dgaf434-B50","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1210\/jc.2008-2103","article-title":"Recurrence of hyperprolactinemia after withdrawal of long-term cabergoline therapy","volume":"94","author":"Kharlip","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2025111718525694000_dgaf434-B51","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/j.1365-2265.2011.04136.x","article-title":"Recurrence of hyperprolactinaemia following discontinuation of dopamine agonist therapy in patients with prolactinoma occurs commonly especially in macroprolactinoma","volume":"75","author":"Barber","year":"2011","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"2025111718525694000_dgaf434-B52","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s11102-011-0303-6","article-title":"Long term follow-up of patients with prolactinomas and outcome of dopamine agonist withdrawal: a single center experience","volume":"15","author":"Anagnostis","year":"2012","journal-title":"Pituitary"},{"issue":"21","key":"2025111718525694000_dgaf434-B53","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1056\/NEJMoa022657","article-title":"Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia","volume":"349","author":"Colao","year":"2003","journal-title":"N Engl J Med"},{"issue":"1","key":"2025111718525694000_dgaf434-B54","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1023\/B:PITU.0000044631.89535.48","article-title":"Medical and surgical management of microprolactinoma","volume":"7","author":"Couldwell","year":"2004","journal-title":"Pituitary"},{"key":"2025111718525694000_dgaf434-B55","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.wneu.2015.10.090","article-title":"Cost-effectiveness analysis of microscopic and endoscopic transsphenoidal surgery versus medical therapy in the management of microprolactinoma in the United States","volume":"87","author":"Jethwa","year":"2016","journal-title":"World Neurosurg"},{"issue":"3","key":"2025111718525694000_dgaf434-B56","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s11102-008-0091-9","article-title":"Quality of life in women with microprolactinoma treated with dopamine agonists","volume":"11","author":"Cesar de Oliveira Naliato","year":"2008","journal-title":"Pituitary"},{"issue":"1","key":"2025111718525694000_dgaf434-B57","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMoa054830","article-title":"Valvular heart disease and the use of dopamine agonists for Parkinson's disease","volume":"356","author":"Zanettini","year":"2007","journal-title":"N Engl J Med"},{"issue":"12","key":"2025111718525694000_dgaf434-B58","doi-asserted-by":"crossref","first-page":"4721","DOI":"10.1210\/jc.2007-2758","article-title":"Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients","volume":"93","author":"Ono","year":"2008","journal-title":"J Clin Endocrinol Metab"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgaf434\/64464415\/dgaf434.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/110\/12\/e4242\/64464415\/dgaf434.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/110\/12\/e4242\/64464415\/dgaf434.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T23:53:18Z","timestamp":1763423598000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/110\/12\/e4242\/8270665"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,1]]},"references-count":58,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,10,1]]},"published-print":{"date-parts":[[2025,11,18]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgaf434","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,10,1]]}}}